GlassScriptPhysician profile
Maria Guevara
NPI 1316124662
$2,054.67
in general payments reported to CMS, 2019-2025
11 companies · $695 in 2025
The $695 reported for 2025 was more than what 77% of Nuclear Imaging & Therapy providers received nationally (typical 2025 total: $122).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $43.04 · 2021: $74.97 · 2022: $765 · 2023: $302 · 2024: $19.89 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,016.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $826.90 | 2022-2025 | Wegovy, Ozempic |
| Alkermes, INC. | $422.37 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $296.06 | 2022-2023 | Breztri |
| Teva Pharmaceuticals USA, INC. | $135.69 | 2023-2024 | Austedo Xr, Uzedy |
| Abbvie INC. | $125.00 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.92 | 2025 | Caplyta |
| Lilly USA, LLC | $42.50 | 2025 | Mounjaro, Zepbound |
| Linus Health, INC. | $27.69 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.63 | 2022 | |
| Covis Pharma Gmbh | $18.87 | 2020 | |
| Evofem Biosciences, INC. | $17.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Guevara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.